Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Webster, Lucy ^a   Groskreutz, Derek ^a   Grinbergs Saull, Anna ^b   Howard, Rob ^a   O'Brien, John T ^c   Mountain, Gail ^d   Banerjee, Sube ^e   Woods, Bob ^f   Perneczky, Robert ^g,h,i   Lafortune, Louise ^j   Roberts, Charlotte ^k   McCleery, Jenny ^l   Pickett, James ^b   Bunn, Frances ^m   Challis, David ⁿ   Charlesworth, Georgina ^a   Featherstone, Katie ^o   Fox, Chris ^p   Goodman, Claire ^m   Jones, Roy ^q   Lamb, Sarah ^r   Moniz Cook, Esme ^s   Schneider, Justine ^t   Shepperd, Sasha ^u   Surr, Claire ^v   Thompson Coon, Jo ^w   Ballard, Clive ^x   Brayne, Carol ^j   Burns, Alistair ^y   Clare, Linda ^w,z   Garrard, Peter ^aa   Kehoe, Patrick ^ab   Passmore, Peter ^ac   Holmes, Clive ^ad   Maidment, Ian ^ae   Robinson, Louise ^af   Livingston, Gill ^a,ag,ah   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ALZHEIMER'S SOCIETY   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

^f BANGOR UNIVERSITY   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k International Consortium for Health Outcomes Measurement (ICHOM)   (United Kingdom)

^l OXFORD HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^m UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

ⁿ UNIVERSITY OF MANCHESTER   (United Kingdom)

^o CARDIFF UNIVERSITY   (United Kingdom)

^p UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^q UNIVERSITY OF BATH   (United Kingdom)

^r UNIVERSITY OF WARWICK   (United Kingdom)

^s UNIVERSITY OF HULL   (United Kingdom)

^t UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^u UNIVERSITY OF OXFORD   (United Kingdom)

^v LEEDS METROPOLITAN UNIVERSITY   (United Kingdom)

^w UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^x KING'S COLLEGE LONDON   (United Kingdom)

^y UNIVERSITY OF MANCHESTER   (United Kingdom)

^z UNIVERSITY OF EXETER   (United Kingdom)

^aa ST GEORGE S HOSPITAL   (United Kingdom)

^ab UNIVERSITY OF BRISTOL   (United Kingdom)

^ac QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^ad UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^ae ASTON UNIVERSITY   (United Kingdom)

^af NEWCASTLE UNIVERSITY   (United Kingdom)

^ag CLAHRC North Thames   (United Kingdom)

^ah CAMDEN AND ISLINGTON NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; TAU PROTEIN;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE; ARTICLE; CAREGIVER; CLINICAL DEMENTIA RATING; COGNITION; CONSENSUS; DAILY LIFE ACTIVITY; DEMENTIA; HUMAN; MENTAL DISEASE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; QUALITY OF LIFE; SYSTEMATIC REVIEW; DISEASE COURSE; INFORMATION PROCESSING; OUTCOME ASSESSMENT; PATHOLOGY; VALIDATION STUDY;

DEMENTIA; DISEASE PROGRESSION; FOCUS GROUPS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE);

EID: 85021661906     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0179521     Document Type: Article

References (57)

1. Lewis F. Estimation of future cases of dementia from those born in 2015. Office of Health Economics Consulting Reports. 2015.
2. PhRMA. Researching Alzheimer's medicines: Setbacks and stepping stones. 2012.
3. Department oHaPMsO. G8 dementia summit declaration. 2013.
4. Lewis F, Karlsberg Schaffer S, Sussex J. The Trajectory of Dementia in the UK-Making a Difference. Office of Health Economics Consulting Reports. 2014.
5. Zoda TE. New Standards in Alzheimer's Disease Trial Design. Therpeutics, Journal for Clinical Studies. 2014; 6(2):44-5.
6. Rubinstein E, Duggan C, Van Landingham B, Thompson D, Warburton W. A call to action: the global response to dementia through policy innovation. 2015.
7. Long R. Challenges to finding treatments for dementia. 2015.
8. Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016; 12(1):60-4. https://doi.org/10.1016/j.jalz.2015.12.003 PMID: 26710325
9. Harrison JK, Noel-Storr AH, Demeyere N, Reynish EL, Quinn TJ. Outcomes measures in a decade of dementia and mild cognitive impairment trials. Alzheimer's Research & Therapy. 2016; 8(1):48.
10. Webster L, Groskreutz D, Grinbergs-Saull A, Howard R, O'Brien JT, Mountain G, et al. Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment 2017; 21(26). https://doi.org/10.3310/hta21260 PMID: 28625273
11. Moniz-Cook E, Vernooij-Dassen M, Woods R, Verhey F, Chattat R, Vugt MD et al. A European consensus on outcome measures for psychosocial intervention research in dementia care. Aging Ment Health. 2008; 12(1):14-29. https://doi.org/10.1080/13607860801919850 PMID: 18297476
12. JPND. Dementia Outcome Measures: Charting New Territory. 2015.
13. ICHOM. Standard Set for Dementia 2016 [21st April 2016]. Available from: http://www.ichom.org/medical-conditions/dementia/.
14. Hancock GA, Woods B, Challis D, Orrell M. The needs of older people with dementia in residential care. International journal of geriatric psychiatry. 2006; 21(1):43-9. https://doi.org/10.1002/gps.1421 PMID: 16323258
15. National Institute for Health Research. ISRCTN93682878 Reducing pathology in Alzheimer's disease through angiotensin targeting [22nd January 2016]. Available from: http://www.isrctn.com/ISRCTN93682878.
16. University of Colorado Denver TDF. NCT01409915 Study of the Safety & Efficacy of Leukine® in the Treatment of Alzheimer's Disease [29th January 2016]. Available from: https://clinicaltrials.gov/ct2/show/NCT01409915.
17. Deardorff WJ, Feen E, Grossberg GT. The use of cholinesterase inhibitors across all stages of Alzheimer's disease. Drugs & aging. 2015; 32(7):537-47.
18. Velayudhan L, Ryu SH, Raczek M, Philpot M, Lindesay J, Critchfield M, et al. Review of brief cognitive tests for patients with suspected dementia. Int Psychogeriatr. 2014; 26(8):1247-62. https://doi.org/10.1017/S1041610214000416 PMID: 24685119
19. Matallana D, de Santacruz C, Cano C, Reyes P, Samper-Ternent R, Markides KS, et al. The relationship between education level and mini-mental state examination domains among older Mexican Americans. Journal of geriatric psychiatry and neurology. 2011; 24(1):9-18. https://doi.org/10.1177/0891988710373597 PMID: 20538969
20. Salmon D, Thal LJ, Butters N, Heindel WC. Longitudinal evaluation of dementia of the Alzheimer type A comparison of 3 standardized mental status examinations. Neurology. 1990; 40(8):1225. PMID: 2381530
21. Skinner J, Carvalho JO, Potter GG, Thames A, Zelinski E, Crane PK, et al. The Alzheimer's disease assessment scale-cognitive-plus (ADAS-Cog-Plus): an expansion of the ADAS-Cog to improve responsiveness in MCI. Brain imaging and behavior. 2012; 6(4):489-501. https://doi.org/10.1007/s11682-012-9166-3 PMID: 22614326
22. Mitchell AJ. The Mini-Mental State Examination (MMSE): an update on its diagnostic validity for cognitive disorders. Cognitive screening instruments: Springer; 2013. p. 15-46.
23. Howard R, Phillips P., Johnson T., O'Brien J., Sheehan B., Lindesay J., et al. Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry. 2011; 26 (8):812-7. https://doi.org/10.1002/gps.2607 PMID: 20848576
24. Rockwood K, Fay S., & Gorman M. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease. Int J Geriatr Psychiatry. 2010; 25(2):191-201. https://doi.org/10.1002/gps.2319 PMID: 19548273
25. Schrag A, Schott J. M., & Alzheimer's Disease Neuroimaging Initiative. What is the clinically relevant change on the ADAS-Cog? J Neurol Neurosurg Psychiatry. 2011; 83:171-3. https://doi.org/10.1136/jnnp-2011-300881 PMID: 22019547
26. Zhou B, Teramukai S, Yoshimura K, Fukushima M. Validity of cerebrospinal fluid biomarkers as endpoints in early-phase clinical trials for Alzheimer's disease. J Alzheimers Dis. 2009; 18(1):89-102. https://doi.org/10.3233/JAD-2009-1124 PMID: 19542628
27. Park SY, Wang MJ, Jang J-W, Park YH, Lee JW, Kim S. Risk Factors for Post-Lumbar Puncture Headache in a Study of Alzheimer's Disease Biomarkers. Dementia and Neurocognitive Disorders. 2015; 14 (1):12-6.
28. Fox N, Black R, Gilman S, Rossor M, Griffith S, Jenkins L, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology. 2005; 64(9):1563-72. PubMed PMID: 2005-04928-008. https://doi.org/10.1212/01.WNL.0000159743.08996.99 PMID: 15883317
29. Li N. Neuroprotective Effects of Cistanches Herba Therapy on Patients with Moderate Alzheimer's Disease. Evid Based Complement Alternat Med. 2015; 2015:1-12 p. https://doi.org/10.1155/2015/103985 PMID: 109571350. Language: English. Entry Date: 20151007. Revision Date: 20151030. Publication Type: Article. Journal Subset: Alternative/Complementary Therapies.
30. Mak E SL, Williams GB, Watson R, Firbank M, Blamire AM, et al. Longitudinal assessment of global and regional atrophy rates in Alzheimer's disease and dementia with Lewy bodies. NeuroImage: Clinical. 2015; 7:456-62.
31. Apostolova L, Zarow C, Biado K, Hurtz S, Boccardi M, J, et al. Relationship between hippocampal atrophy and neuropathology markers: A 7T MRI validation study of the EADC-ADNI Harmonized Hippocampal Segmentation Protocol. Alzheimers Dement. 2015; 11(2):139-50. https://doi.org/10.1016/j.jalz. 2015.01.001 PMID: 25620800
32. Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, et al. Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J Nutr Health Aging. 2009; 13(6):550-7. PMID: 19536424.
33. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med. 2013; 369(4):341-50. https://doi.org/10.1056/NEJMoa1210951 PMID: 23883379.
34. Galasko D, Bell J, Mancuso JY, Kupiec JW, Sabbagh MN, van Dyck C, et al. Clinical trial of an inhibitor of RAGE-Abeta interactions in Alzheimer disease. Neurology. 2014; 82(17):1536-42. PubMed Central PMCID: PMCPMC4011464 [Available on 04/29/15]. https://doi.org/10.1212/WNL.0000000000000364 PMID: 24696507
35. Ryu S, Katona C, Rive B, Livingston G. Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months-The LASER-AD study. Am J Geriatr Psychiatry. 2005; 13(11):976-83. https://doi.org/10.1176/appi.ajgp.13.11.976 PMID: 16286441
36. Spalletta G, Musicco M, Padovani A, Rozzini L, Perri R, Fadda L et al. Neuropsychiatric symptoms and syndromes in a large cohort of newly diagnosed, untreated patients with Alzheimer disease. Am J Geriatr Psychiatry 2010; 18(11):1026-35. https://doi.org/10.1097/JGP.0b013e3181d6b68d PMID: 20808086
37. Martyr A, Clare L. Awareness of functional ability in people with early-stage dementia. International Journal of Geriatric Psychiatry. 2017.
38. Gold DA. An examination of instrumental activities of daily living assessment in older adults and mild cognitive impairment. Journal of clinical and experimental neuropsychology. 2012; 34(1):11-34. https://doi.org/10.1080/13803395.2011.614598 PMID: 22053873
39. Banerjee S, Smith SC, Lamping DL, Harwood RH, Foley B, Smith P, et al. Quality of life in dementia: more than just cognition-an analysis of associations with quality of life in dementia. J Neurol Neurosurg Psychiatry 2006; 77:146-8. https://doi.org/10.1136/jnnp.2005.072983 PMID: 16421113
40. Banerjee S, Samsi K, Petrie CD, Alvir J, Treglia M, Schwam EM, et al. What do we know about quality of life in dementia? A review of the emerging evidence on the predictive and explanatory value of disease specific measures of health related quality of life in people with dementia. Int J Geriatr Psychiatry. 2009; 24(1):15-24. https://doi.org/10.1002/gps.2090 PMID: 18727132
41. Banerjee S. Commentary on "Health economics and the value of therapy in Alzheimer's disease." Quality of life in dementia: Development and use of a disease-specific measure of health-related quality of life in dementia. Alzheimers Dement. 2007; 3(3):166-71. https://doi.org/10.1016/j.jalz.2007.04.384 PMID: 19595933
42. Folstein M, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-98. PMID: 1202204
43. Rosen W, Mohs R, Davis K. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141 (11):1356-64. https://doi.org/10.1176/ajp.141.11.1356 PMID: 6496779
44. Gelinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther. 1999; 53(5):471-81. PMID: 10500855
45. Cummings J, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994; 44 (12):2308-14. PMID: 7991117
46. Smith S, Lamping DL, Banerjee S, Harwood R, Foley B, Smith P. Measurement of health-related quality of life for people with dementia: development of a new instrument (DEMQOL) and an evaluation of current methodology. Health Technol Assess 2005; 9(10). PMID: 15774233
47. Hughes C, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-72. PMID: 7104545
48. OECD. Enhancing Translational Research and Clinical Development for Alzheimer's Disease and other Dementias. Paris.: 2015.
49. Galimberti D, Scarpini E. Emerging amyloid disease modifying drugs for Alzheimer's disease. Expert Opin Emerg Drugs. 2016; 21(1):5-6. https://doi.org/10.1517/14728214.2016.1146678 PMID: 26817686
50. FDA. Guidance for Industry Alzheimer's Disease: Developing Drugs for the Treatment of Early Stage Disease. 2013.
51. European Medicines Agency. Draft guideline on the clinical investigation of medicines for the treatment of Alzheimer's disease and other dementias. 2016.
52. Vellas B, Andrieu S, Sampaio C, Wilcock G. Disease-modifying trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2007; 6(1):56-62. https://doi.org/10.1016/S1474-4422(06) 70677-9 PMID: 17166802
53. Vellas B, Andrieu S, Sampaio C, Coley N, Wilcock G. Endpoints for trials in Alzheimer's disease: a European task force consensus. Lancet Neurol. 2008; 7(5):436-50. https://doi.org/10.1016/S1474-4422(08)70087-5 PMID: 18420157
54. Newman JC. Copyright and bedside cognitive testing: Why we need alternatives to the Mini-Mental State Examination. JAMA internal medicine. 2015; 175(9):1459-60. https://doi.org/10.1001/jamainternmed.2015.2159 PMID: 26053392
55. Duits F, Martinez-Lage P, Paquet C, Engelborghs S, Lleó A, Hausner L, et al Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. Alzheimers Dement. 2016; 12(2):154-63. https://doi.org/10.1016/j.jalz.2015.08.003 PMID: 26368321
56. Brookmeyer R, Kawas CH, Abdallah N, Paganini-Hill A, Kim RC, Corrada MM. Impact of interventions to reduce Alzheimer's disease pathology on the prevalence of dementia in the oldest-old. Alzheimers Dement. 2016; 12(3):225-32. https://doi.org/10.1016/j.jalz.2016.01.004 PMID: 26900132
57. Krieger N. Epidemiology and the web of causation: has anyone seen the spider?. Social Science and Medicine. 1994; 39(7):887-903. PMID: 7992123